148 related articles for article (PubMed ID: 12085265)
1. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener RA
Br J Cancer; 2002 Jul; 87(1):106-12. PubMed ID: 12085265
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
Demartis S; Tarli L; Borsi L; Zardi L; Neri D
Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides.
Niesner U; Halin C; Lozzi L; Günthert M; Neri P; Wunderli-Allenspach H; Zardi L; Neri D
Bioconjug Chem; 2002; 13(4):729-36. PubMed ID: 12121127
[TBL] [Abstract][Full Text] [Related]
4. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
[TBL] [Abstract][Full Text] [Related]
5. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
6. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.
Viti F; Tarli L; Giovannoni L; Zardi L; Neri D
Cancer Res; 1999 Jan; 59(2):347-52. PubMed ID: 9927045
[TBL] [Abstract][Full Text] [Related]
7. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris.
Marty C; Scheidegger P; Ballmer-Hofer K; Klemenz R; Schwendener RA
Protein Expr Purif; 2001 Feb; 21(1):156-64. PubMed ID: 11162401
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic tumor targeting with scFv antibody-modified liposomes.
Marty C; Schwendener RA
Methods Mol Med; 2005; 109():389-402. PubMed ID: 15585933
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
[TBL] [Abstract][Full Text] [Related]
12. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
Ishii H; Zahra MH; Takayanagi A; Seno M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
[TBL] [Abstract][Full Text] [Related]
13. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
Ebbinghaus C; Ronca R; Kaspar M; Grabulovski D; Berndt A; Kosmehl H; Zardi L; Neri D
Int J Cancer; 2005 Aug; 116(2):304-13. PubMed ID: 15800913
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.
Marty C; Langer-Machova Z; Sigrist S; Schott H; Schwendener RA; Ballmer-Hofer K
Cancer Lett; 2006 Apr; 235(2):298-308. PubMed ID: 15953677
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity human antibody that targets tumoral blood vessels.
Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
[TBL] [Abstract][Full Text] [Related]
16. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
17. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
[TBL] [Abstract][Full Text] [Related]
19. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.
Neri D; Carnemolla B; Nissim A; Leprini A; Querzè G; Balza E; Pini A; Tarli L; Halin C; Neri P; Zardi L; Winter G
Nat Biotechnol; 1997 Nov; 15(12):1271-5. PubMed ID: 9359110
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
